Post Profile






AstraZeneca's Brilinta fails in peripheral artery disease trial

LONDON (Reuters) - AstraZeneca said on Tuesday its heart drug Brilinta failed to show any benefit over an existing medicine in treating peripheral artery disease (PAD) in a large-scale clinical trial.
read more

share

Related Posts


Clinical trials, ain't the a bitch! Astra's Crestor drug fails to beat Pfizer's Lipitor - Yahoo!

Medical / Pharmaceutical : PharmaGossip

LONDON/ZURICH (Reuters) - AstraZeneca Plc's key cholesterol drug Crestor failed to beat Pfizer Inc's Lipitor in a head-to-head clinical study, limiting any protection the British company will get as its U.S. rival faces competition ...

AstraZeneca starts new heart drug study

Business & Finance : Business Report

AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients. ||| AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with ...

For AZ's Onglyza SAVOUR is not a saviour

Medical / Pharmaceutical : PharmaGossip

AstraZeneca has suffered another drug trial setback. Its diabetes drug Onglyza, developed with Bristol-Myers Squibb, failed to reduce heart risks or strokes in a large scale clinical trial. Despite investor hopes, the Savor trial sh...

How brilliant is Brilinta?

Medical / Pharmaceutical : PharmaGossip

AstraZeneca US drug trial queried AstraZeneca's chief executive Pascal Soriot says he is very confident in the findings of the clinical trial of heart drug Brilinta. Photograph: Lynne Cameron/PA AstraZeneca is being investigated by ...

U.S. clears AstraZeneca over heart drug trial

News : The Newsroom

LONDON (Reuters) - AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned. The decision last O...

Comments


Copyright © 2016 Regator, LLC